COST-EFFECTIVENESS OF RIVAROXABAN WITHIN SUBGROUPS FOR ATRIAL FIBRILLATION AND VENOUS THROMBOEMBOLISM IN THE NETHERLANDS

被引：0
|
作者：
Gout-Zwart, J. [1 ]
Sediq, A. [1 ]
van den Bosch, M. [2 ]
Postma, M. J. [1 ]
机构：
[1] Univ Groningen, Groningen, Netherlands
[2] Bayer BV, Mijdrecht, Netherlands
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.1758
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV90
引用
收藏
页码：A652 / A652
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness of catheter ablation for atrial fibrillation
    Khaykin, Yaariv
    CURRENT OPINION IN CARDIOLOGY, 2007, 22 (01) : 11 - 17
  • [42] Postpartum venous thromboembolism prophylaxis: A Cost-Effectiveness Analysis
    Becker, David A.
    Einerson, Brett D.
    Wetta, Luisa L.
    Kuper, Spencer G.
    Casey, Brian M.
    Subramaniam, Akila
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2019, 220 (01) : S487 - S488
  • [43] Cost-effectiveness of atrial fibrillation catheter ablation
    Andrikopoulos, George
    Tzeis, Stylianos
    Maniadakis, Nikos
    Mavrakis, Hercules E.
    Vardas, Panos E.
    EUROPACE, 2009, 11 (02): : 147 - 151
  • [44] Efficacy and Cost-Effectiveness of Dabigatran Etexilate Versus Warfarin in Atrial Fibrillation in Different Age Subgroups
    Clemens, Andreas
    Peng, Siyang
    Brand, Sarah
    Brueckmann, Martina
    Kansal, Anuraag
    Lim, Jonathan
    Noack, Herbert
    Sander, Stephen
    Sorensen, Sonja
    AMERICAN JOURNAL OF CARDIOLOGY, 2014, 114 (06): : 849 - 855
  • [45] COST-EFFECTIVENESS OF RIVAROXABAN VERSUS WARFARIN FOR TREATMENT OF NONVALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH WORSENING RENAL FUNCTION
    Salcedo, J.
    Hay, J. W.
    Lam, J.
    VALUE IN HEALTH, 2018, 21 : S61 - S61
  • [46] COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN VERSUS DABIGATRAN AND ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP REPLACEMENT
    Vorobyev, P.
    Krasnova, L.
    Borisenko, O.
    Lukyantseva, D.
    Bashlakova, E.
    VALUE IN HEALTH, 2011, 14 (03) : A40 - A40
  • [47] The Study of Cost-Effectiveness of Rivaroxaban versus Warfarin in Patients with Atrial Fibrillation Who Developed Ischemic Stroke
    Jaberi, Neda
    Kavosi, Zahra
    Hooshmandi, Etrat
    Moradi, Nasrin
    Keshavarz, Khosro
    Borhani-Haghighi, Afshin
    STROKE RESEARCH AND TREATMENT, 2021, 2021
  • [48] Cost-effectiveness of Dabigatran Compared With Rivaroxaban for Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in China
    Dong, Shu-Jie
    Wu, Bin
    Zhai, Suo-Di
    Zhang, Yan-Jun
    Chu, Yun-Bo
    Gupta, Parul
    Li, Ya-Huei
    CLINICAL THERAPEUTICS, 2020, 42 (01) : 144 - 156
  • [49] Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism
    de Jong, Lisa A.
    van der Velden, Annette W. G.
    van Hulst, Marinus
    Postma, Maarten J.
    BMJ OPEN, 2020, 10 (11):
  • [50] COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP AND KNEE REPLACEMENT IN EUROPE
    Monreal, M.
    Ryttberg, L.
    Diamantopoulos, A.
    Lees, M.
    Negrini, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 50 - 51
12345